ASTRAZENECA PLCASTRAZENECA PLCASTRAZENECA PLC

ASTRAZENECA PLC

No trades
See on Supercharts

Key facts today


AstraZeneca's Enhertu, in partnership with Daiichi Sankyo, showed a 30% lower death risk in a Phase 3 trial for second-line HER2 positive gastric cancer, with median survival of 14.7 months.
AstraZeneca's DATROWAY showed strong results in lung cancer trials, with response rates over 54% and disease control rates up to 95%. Safety profiles remained consistent across studies.
AstraZeneca partners with M42 and SOPHiA Genetics to introduce liquid biopsy testing in the UAE, targeting lung, ovarian, and breast cancers in select hospitals starting next year.
Analyze the impactAnalyze the impact
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪4.27 T‬MXN
51.36MXN
‪146.68 B‬MXN
‪1.13 T‬MXN
‪3.10 B‬
Beta (1Y)
0.23

About ASTRAZENECA PLC ORD USD0.25


CEO
Pascal Soriot
Headquarters
Cambridge
Founded
1992
FIGI
BBG000C28SY4
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
US46353AX6
ASTRAZENECA 20/50
Yield to maturity
7.45%
Maturity date
Aug 6, 2050
US46353AZ1
ASTRAZENECA 21/51
Yield to maturity
6.78%
Maturity date
May 28, 2051
US46353AU2
ASTRAZENECA 18/48
Yield to maturity
6.08%
Maturity date
Aug 17, 2048
AZN3901525
AstraZeneca PLC 4.0% 18-SEP-2042
Yield to maturity
6.06%
Maturity date
Sep 18, 2042
US46353AM0
ASTRAZENECA PLC 15/45
Yield to maturity
6.02%
Maturity date
Nov 16, 2045
AZN.GE
AstraZeneca PLC 6.45% 15-SEP-2037
Yield to maturity
5.14%
Maturity date
Sep 15, 2037
A
US4636NAN3
ASTRAZEN.FI. 24/34
Yield to maturity
4.91%
Maturity date
Feb 26, 2034
A
AZN5193314
AstraZeneca Finance LLC 2.25% 28-MAY-2031
Yield to maturity
4.83%
Maturity date
May 28, 2031
A
AZN5549116
AstraZeneca Finance LLC 4.875% 03-MAR-2033
Yield to maturity
4.82%
Maturity date
Mar 3, 2033
US46353AW8
ASTRAZENECA 20/30
Yield to maturity
4.81%
Maturity date
Aug 6, 2030
50UC
ASTRAZENECA PLC 5.75% SNR EMTN 13/11/2031
Yield to maturity
4.58%
Maturity date
Nov 13, 2031

See all AZN/N bonds 


Check out other big names from the same industry as AZN/N.